Breaking News Instant updates and real-time market news.

SNY

Sanofi

$47.93

-0.0378 (-0.08%)

, MRK

Merck

$62.30

-0.54 (-0.86%)

15:33
08/08/17
08/08
15:33
08/08/17
15:33

Sanofi announces filing of patent infringement suit against Merck

Sanofi (SNY) announced that it filed a patent infringement suit against Merck (MRK) on August 8 in the United States District Court for the District of New Jersey. In its suit Sanofi alleges infringement of two patents. The suit was triggered by a notification received from Merck in late June, in which Merck stated that it had filed an NDA with FDA for an insulin glargine vial drug product. Merck also stated that its NDA included a paragraph IV certification challenging all of the Sanofi patents then listed in the FDA Orange Book for Sanofi's Lantus and Lantus SoloStar products.

SNY

Sanofi

$47.93

-0.0378 (-0.08%)

MRK

Merck

$62.30

-0.54 (-0.86%)

  • 28

    Aug

  • 22

    Sep

SNY Sanofi
$47.93

-0.0378 (-0.08%)

07/10/17
PIPR
07/10/17
NO CHANGE
Target $126
PIPR
Overweight
Alnylam shares overreacting to ALT elevations in OLE data, says Piper Jaffray
Alnylam (ALNY) and partner Sanofi (SNY) presented new Phase II open-label extension study data on 33 hemophilia patients being treated with fitusiran and reported that eleven patients reported asymptomatic ALT increases, up from three observed in its ASH meeting update, noted Piper Jaffray analyst Edward Tenthoff. However, he thinks the stock is overreacting, as the liver enzyme elevations were asymptomatic and largely reversed within one month, he tells investors. Tenthoff, who also sees the efficacy data as encouraging, reiterates his Overweight rating and $126 price target on Alnylam shares.
07/14/17
WELS
07/14/17
NO CHANGE
Target $41
WELS
Outperform
Wells says smallpox vaccine deal an 'excellent fit' for Emergent BioSolutions
Wells Fargo analyst David Maris said Emergent BioSolutions' (EBS) deal to acquire the ACAM2000 smallpox vaccine business of Sanofi (SNY) is "an excellent fit" and he is "encouraged" by its ability to identify and make a deal for such a "solid target." Maris keeps an Outperform rating and $41 price target on Emergent BioSolutions.
07/31/17
PIPR
07/31/17
NO CHANGE
Target $557
PIPR
Overweight
Regeneron indicated lower after Sanofi earnings report, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says shares of Regeneron (REGN) are indicated lower after partner Sanofi (SNY) reported Q2 U.S. Dupixent sales of $30M in adults with atopic dermatitis. This was essentially in line with the consensus estimate of $33M, Tenthoff tells investors in a research note. He adds that over 5,100 physicians have prescribed and over 13,000 atopic dermatitis patients have been prescribed Dupixent as of July 26. The analyst views the launch stats as impressive and reiterates an Overweight rating on Regeneron with a $557 price target.
07/31/17
ADAM
07/31/17
NO CHANGE
Target $522
ADAM
Buy
Dupixent authorization approval rate outweighs Q2 miss, says Canaccord
Regeneron (REGN) partner Sanofi (SNY) reported a "very high" 73%-83% prior authorization approval rate for Dupixent in Q2, which Canaccord analyst John Newman said outweighs the fact that sales for the drug at $30.6M were slightly below the $33M consensus forecast. The analyst, who sees rapid payor acceptance of Dupixent as "much more crucial" than the initial quarterly revenue, keeps a Buy rating and $522 price target on Regeneron shares.
MRK Merck
$62.30

-0.54 (-0.86%)

07/27/17
GSCO
07/27/17
NO CHANGE
GSCO
Merck could trade up $5 following AstraZeneca MYSTIC failure, says Goldman Sachs
Goldman analyst Jami Rubin expects Merck (MRK) to trade up approximately $5 based on sentiment following AstraZeneca's MYSTIC failure as it partially de-risks longer-term estimates for Keytruda. As a result, the analyst raised Merck's Keytruda sales estimates by $600M in 2018 and $1B in 2019 and beyond, increasing earnings estimates by 14c-20c, and raising his price target on shares to $74 from $70. Rubin cautions that long-term estimates could be at risk if other competitor trials are successful. The analyst rates Merck a Neutral.
07/27/17
FBCO
07/27/17
NO CHANGE
FBCO
Merck unlikely to buy PARP company after Astra deal, says Credit Suisse
Credit Suisse analyst Alethia Young believes Merck (MRK) is unlikely to acquire a PARP inhibitor company like Tesaro (TSRO) or Clovis (CLVS) after inking an immuno-oncology deal with AstraZeneca (AZN).
07/27/17
JANY
07/27/17
NO CHANGE
Target $107
JANY
Buy
PARP deals may make Clovis more attractive buyout candidate, says Janney
The partnerships announced today between AstraZeneca (AZN) and Merck (MRK) as well as Tesaro (TSRO) and Takeda highlight pharma's willingness to expand on PARP's, Janney analyst Debjit Chattopadhyay tells investors in a research note. Clovis' (CLVS) Rubraca is now the only unencumbered PARP and is "far cheaper" on a relative valuation basis than peer Tesaro, the analyst adds. He believes Clovis could now become a more compelling takeover candidate. Chattopadhyay has a Buy rating on the shares with a $107 price target. The stock in midday trading is up 7%, or $5.90, to $93.33.
07/28/17
RHCO
07/28/17
NO CHANGE
RHCO
Merck, AstraZeneca deal positive, says SunTrust
After Merck (MRK) paid $1.6B upfront for access to Astrazeneca's (AZN) PARP inhibitor, Lynparza and another drug, SunTrust analyst John Boris says that the deal "makes strategic/financial sense and validates the PARP inhibitor class." He adds that the companies are "ideally positioned" to leverage a combination of IO and PARP therapies. The analyst reiterates a $73 price target and a Buy rating on Merck.

TODAY'S FREE FLY STORIES

SEDG

SolarEdge

$48.95

1.25 (2.62%)

, JBL

Jabil Circuit

$26.87

-0.12 (-0.44%)

12:25
06/19/18
06/19
12:25
06/19/18
12:25
Recommendations
SolarEdge, Jabil Circuit analyst commentary  »

SolarEdge included in…

SEDG

SolarEdge

$48.95

1.25 (2.62%)

JBL

Jabil Circuit

$26.87

-0.12 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

CVS

CVS Health

$70.37

2.64 (3.90%)

12:25
06/19/18
06/19
12:25
06/19/18
12:25
Options
CVS Health call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:21
06/19/18
06/19
12:21
06/19/18
12:21
Conference/Events
Stephens banking analyst to hold an analyst/industry conference call »

Banking Analyst McEvoy,…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
06/19/18
06/19
12:17
06/19/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
06/19/18
06/19
12:16
06/19/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
06/19/18
06/19
12:15
06/19/18
12:15
Conference/Events
Stephens food/agribusiness analyst to hold an analyst/industry conference call »

Food & Agribusiness…

MUX

McEwen Mining

$2.18

0.035 (1.64%)

12:13
06/19/18
06/19
12:13
06/19/18
12:13
Hot Stocks
McEwen Mining COO Xavier Ochoa to resign effective July 13 »

On June 13, Xavier Ochoa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GFN

General Finance Corp

$11.85

-0.05 (-0.42%)

12:10
06/19/18
06/19
12:10
06/19/18
12:10
Hot Stocks
Havner Family Trust buys 10K shares of General Finance »

The Havner Family Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LVS

Las Vegas Sands

$79.70

-0.83 (-1.03%)

12:10
06/19/18
06/19
12:10
06/19/18
12:10
Options
Put buyer opens downside hedge in Las Vegas Sands after record high »

Put buyer opens downside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

PTC

PTC

$97.72

-0.08 (-0.08%)

12:07
06/19/18
06/19
12:07
06/19/18
12:07
Hot Stocks
PTC, Elysium announce new design, validation app for ThingWorx Navigate »

PTC announced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMI

Kinder Morgan

$17.21

0.04 (0.23%)

12:05
06/19/18
06/19
12:05
06/19/18
12:05
Options
Kinder Morgan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$60.53

0.16 (0.27%)

, S

Sprint

$5.56

0.01 (0.18%)

12:03
06/19/18
06/19
12:03
06/19/18
12:03
Hot Stocks
T-Mobile, Sprint officially file merger plans with FCC »

T-Mobile US (TMUS) and…

TMUS

T-Mobile

$60.53

0.16 (0.27%)

S

Sprint

$5.56

0.01 (0.18%)

DTEGY

Deutsche Telekom

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$195.71

-2.59 (-1.31%)

12:01
06/19/18
06/19
12:01
06/19/18
12:01
Periodicals
Facebook misses 'deadline' to answer Senator's questions, Bloomberg says »

Facebook has missed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

TCI

Transcontinental Realty Inc

$36.00

2.54 (7.59%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Hot Stocks
Transcontinental Realty, Adobe Properties say advisor may make stock purchases »

Transcontinental Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMAR

Smartsheet

$29.00

-3.07 (-9.57%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Hot Stocks
Smartsheet falls -9.9% »

Smartsheet is down -9.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYX

Systemax

$35.40

-4 (-10.15%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Hot Stocks
Systemax falls -10.5% »

Systemax is down -10.5%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$125.30

-2.2 (-1.73%)

, EADSY

Airbus

$0.00

(0.00%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Periodicals
Pratt & Whitney close to fix for part that delayed Airbus jets, Bloomberg says »

Pratt & Whitney,…

UTX

United Technologies

$125.30

-2.2 (-1.73%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$27.24

-4.92 (-15.30%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Hot Stocks
PagSeguro Digital falls -15.1% »

PagSeguro Digital is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

EBR

Centrais Electricas

$3.71

0.21 (6.00%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Hot Stocks
Centrais Electricas rises 6.3% »

Centrais Electricas is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$10.44

0.795 (8.24%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Hot Stocks
ProShares Trust Ultra VIX Short Term Futures ETF rises 8.0% »

ProShares Trust Ultra VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COTV

Cotiviti Holdings

$44.02

4.13 (10.35%)

12:00
06/19/18
06/19
12:00
06/19/18
12:00
Hot Stocks
Cotiviti Holdings rises 10.4% »

Cotiviti Holdings is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARRY

Array BioPharma

$17.90

0.4 (2.29%)

11:57
06/19/18
06/19
11:57
06/19/18
11:57
Conference/Events
Array BioPharma to hold a conference call »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 30

    Jun

  • 30

    Jun

VZ

Verizon

$48.69

1.23 (2.59%)

11:57
06/19/18
06/19
11:57
06/19/18
11:57
Periodicals
Verizon to cease sharing phone-location data of customers, Reuters reports »

Verizon will stop sharing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

USCR

U.S. Concrete

$63.30

-1.1 (-1.71%)

11:53
06/19/18
06/19
11:53
06/19/18
11:53
Hot Stocks
U.S. Concrete rating downgraded to B2 from B1 by Moody's »

Moody's Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

JD

JD.com

$41.57

-2.18 (-4.98%)

11:50
06/19/18
06/19
11:50
06/19/18
11:50
Options
Continued interest in JD Jun 22nd 45 calls even as shares slide »

Continued interest in JD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.